Things are getting hectic in the tranquil Taunus.
Surprisingly for outsiders, Carla Kriwet resigned from her position as CEO of Fresenius Medical Care (FMC) after only two months.
Actually far too short for the manager to have made any real mistakes during her tenure.
With their decision, which, as is usual in such cases, is communicated as being by mutual agreement, the truth is that a short showdown ends, from which Michael Sen, head of the parent company Fresenius SE, emerges as the clear winner.
The former Siemens and Eon manager is the strong man at the head of the Bad Homburg healthcare group, after he also inherited the unsuccessful Stefan Sturm two months ago.
The stock market favorite Fresenius has recently disappointed investors several times.
In the FAZ, Sen promised to tackle the problems quickly and send a positive signal to the markets soon.
Crucial to this is the performance of its troubled subsidiary FMC, which is a major contributor to profits and sales.
Today his statement appears in a different light, he is "also an active investor in FMC".
For Kriwet, the previous head of finance, Helen Giza, will take over the FMC leadership.
The rational Sen should get along with her.
He has to.
In what is by far the most important market, the USA, the dialysis group is still facing problems ranging from a shortage of skilled workers to changes in the healthcare system.
With 30 percent, the parent company still dominates FMC.
Investors are pushing for at least a downsizing, if not a spin-off.
This external pressure should still come in handy for Michael Sen for his restructuring of the sluggish conglomerate.
But it is also clear: After Kriwet's departure, the pressure on Sen increases even more to present quick successes.